{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:44:06Z","timestamp":1791420246730,"version":"4.3.3"},"reference-count":226,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":4266,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1016\/j.ymthe.2004.10.015","type":"journal-article","created":{"date-parts":[[2004,12,16]],"date-time":"2004-12-16T05:42:41Z","timestamp":1103175761000},"page":"180-195","source":"Crossref","is-referenced-by-count":85,"title":["Fighting Cancer with Vaccinia Virus: Teaching New Tricks to an Old Dog"],"prefix":"10.1016","volume":"11","author":[{"given":"Yuqiao","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Nemunaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2004.10.015_bib1","first-page":"5770","article-title":"Vector-based vaccine\/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity","volume":"62","author":"Aarts","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/PL00006677","article-title":"MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines","volume":"48","author":"Acres","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2004.10.015_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0923-2494(05)80044-6","article-title":"CTL immunity and cytokine regulation in viral infection","volume":"145","author":"Ada","year":"1994","journal-title":"Res. Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib4","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0264-410X(00)00488-6","article-title":"Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer","volume":"19","author":"Adams","year":"2001","journal-title":"Vaccine"},{"issue":"Pt 4","key":"10.1016\/j.ymthe.2004.10.015_bib5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1099\/0022-1317-80-4-949","article-title":"Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors","volume":"80","author":"Alcami","year":"1999","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0092-8674(92)90274-G","article-title":"A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection","volume":"71","author":"Alcami","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2004.10.015_bib7","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1128\/JVI.69.8.4633-4639.1995","article-title":"Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity","volume":"69","author":"Alcami","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.4049\/jimmunol.160.2.624","article-title":"Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus","volume":"160","author":"Alcami","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/viro.1998.9123","article-title":"The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses","volume":"244","author":"Antoine","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2004.10.015_bib10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s002620000145","article-title":"The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines","volume":"49","author":"Arlen","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2004.10.015_bib11","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1128\/JVI.66.8.4710-4719.1992","article-title":"Mutational analysis of the core, spacer, and initiator regions of vaccinia virus intermediate-class promoters","volume":"66","author":"Baldick","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4781(02)00249-X","article-title":"Targeted adenoviral vectors","volume":"1575","author":"Barnett","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2004.10.015_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0092-8674(82)90349-X","article-title":"Incompletely base-paired flip-flop terminal loops link the two DNA strands of the vaccinia virus genome into one uninterrupted polynucleotide chain","volume":"28","author":"Baroudy","year":"1982","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2004.10.015_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0264-410X(98)00207-2","article-title":"Edward Jenner's inquiry: a bicentenary analysis","volume":"17","author":"Baxby","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2004.10.015_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0042-6822(91)90158-8","article-title":"Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon","volume":"183","author":"Beattie","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2004.10.015_bib16","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1073\/pnas.1233578100","article-title":"Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses","volume":"100","author":"Belyakov","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2004.10.015_bib17","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2002.08.017","article-title":"Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review","volume":"20","author":"Berinstein","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2004.10.015_bib19","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1128\/JVI.26.3.554-569.1978","article-title":"Sequence complexity and relative abundance of vaccinia virus mRNA's synthesized in vivo and in vitro","volume":"26","author":"Boone","year":"1978","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib20","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1099\/vir.0.18942-0","article-title":"Vaccinia virus transcription","volume":"84","author":"Broyles","year":"2003","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib21","first-page":"135","article-title":"An in vitro transcription system for studying vaccinia virus early genes","volume":"269","author":"Broyles","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/MMBR.55.1.80-122.1991","article-title":"Poxvirus pathogenesis","volume":"55","author":"Buller","year":"1991","journal-title":"Microbiol. Rev."},{"key":"10.1016\/j.ymthe.2004.10.015_bib23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/317813a0","article-title":"Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype","volume":"317","author":"Buller","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2004.10.015_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1006\/viro.2000.0689","article-title":"Orthopoxvirus IL-18 binding proteins: affinities and antagonist activities","volume":"279","author":"Calderara","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2004.10.015_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.immunol.20.091101.091806","article-title":"The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses","volume":"20","author":"Carreno","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib26","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/jnci\/90.24.1881","article-title":"Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen","volume":"90","author":"Carroll","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2004.10.015_bib27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1006\/viro.1993.1292","article-title":"Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA","volume":"194","author":"Chang","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2004.10.015_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00002371-200101000-00006","article-title":"Low-dose vaccinia virus-mediated cytokine gene therapy of glioma","volume":"24","author":"Chen","year":"2001","journal-title":"J. Immunother."},{"key":"10.1016\/j.ymthe.2004.10.015_bib29","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nrc948","article-title":"Oncolytic viruses","volume":"2","author":"Chiocca","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2004.10.015_bib30","doi-asserted-by":"crossref","first-page":"15974","DOI":"10.1074\/jbc.270.27.15974","article-title":"Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling","volume":"270","author":"Colamonici","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2004.10.015_bib31","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1089\/hum.1996.7.11-1381","article-title":"Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge","volume":"7","author":"Cole","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib32","series-title":"Immunology of Poxviruses","author":"Cole","year":"1982"},{"key":"10.1016\/j.ymthe.2004.10.015_bib33","first-page":"34","article-title":"Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia\u2013CEA vaccine","volume":"6","author":"Conry","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib34","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1089\/104303402753812520","article-title":"Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus","volume":"13","author":"Corona Gutierrez","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/10430340460745757","article-title":"Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus","volume":"15","author":"Corona Gutierrez","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1749-6632.1999.tb09409.x","article-title":"Strategies to adapt adenoviral vectors for targeted delivery","volume":"886","author":"Curiel","year":"1999","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.ymthe.2004.10.015_bib37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1083\/jcb.10.4.475","article-title":"The development of vaccinia virus in Earle's L strain cells as examined by electron microscopy","volume":"10","author":"Dales","year":"1961","journal-title":"J. Biophys. Biochem. Cytol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib38","first-page":"6032","article-title":"Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16\/18 oncoproteins","volume":"63","author":"Davidson","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib39","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/0022-2836(89)90107-1","article-title":"Structure of vaccinia virus early promoters","volume":"210","author":"Davison","year":"1989","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0022-2836(89)90108-3","article-title":"Structure of vaccinia virus late promoters","volume":"210","author":"Davison","year":"1989","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(02)00008-6","article-title":"Cidofovir in the treatment of poxvirus infections","volume":"55","author":"De Clercq","year":"2002","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib42","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.14.2.382-397.2001","article-title":"Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections","volume":"14","author":"De Clercq","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ymthe.2004.10.015_bib43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bmb\/62.1.149","article-title":"Cancer vaccines and immunotherapy","volume":"62","author":"Dermime","year":"2002","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.ymthe.2004.10.015_bib44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0042-6822(76)90116-1","article-title":"Biogenesis of vaccinia: specific inhibition of rapidly labeled host DNA in vaccinia inoculated cells","volume":"71","author":"des Gouttes Olgiati","year":"1976","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2004.10.015_bib45","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib46","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1089\/104303403322319426","article-title":"Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial","volume":"14","author":"Di Nicola","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib47","first-page":"291","article-title":"Replicating adenoviruses in cancer therapy","volume":"273","author":"Dobbelstein","year":"2004","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib48","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00000441-190412740-00001","article-title":"Rabies virus vaccination in a patient with cervical carcinoma","volume":"127","author":"Dock","year":"1904","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.ymthe.2004.10.015_bib49","first-page":"106","article-title":"Technology evaluation: TG-1031, Transgene SA","volume":"2","author":"Doehn","year":"2000","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib50","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1128\/JVI.64.10.4884-4892.1990","article-title":"Fusion of intra- and extracellular forms of vaccinia virus with the cell membrane","volume":"64","author":"Doms","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib51","first-page":"4955","article-title":"Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo","volume":"59","author":"Drexler","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib52","first-page":"1632","article-title":"A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer","volume":"6","author":"Eder","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib53","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0042-6822(92)90535-W","article-title":"A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope","volume":"188","author":"Engelstad","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2004.10.015_bib54","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1126\/science.298.5602.2313","article-title":"Public health. Treating vaccine reactions: two lifelines, but no guarantees","volume":"298","author":"Enserink","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2004.10.015_bib55","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.4049\/jimmunol.170.6.3401","article-title":"CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model","volume":"170","author":"Espenschied","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib56","series-title":"Poxviruses","author":"Esposito","year":"2001"},{"key":"10.1016\/j.ymthe.2004.10.015_bib57","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1099\/0022-1317-19-2-201","article-title":"Early virus protein synthesis in vaccinia virus-infected cells","volume":"19","author":"Esteban","year":"1973","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib58","series-title":"The Orthopoxviruses","author":"Fenner","year":"1989"},{"key":"10.1016\/j.ymthe.2004.10.015_bib59","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","article-title":"Smallpox vaccination: a review. Part II. Adverse events","volume":"37","author":"Fulginiti","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ymthe.2004.10.015_bib60","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0952-7915(00)00191-6","article-title":"Danger signals: SOS to the immune system","volume":"13","author":"Gallucci","year":"2001","journal-title":"Curr. Opin. Immunol."},{"issue":"Pt 11","key":"10.1016\/j.ymthe.2004.10.015_bib61","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1099\/0022-1317-78-11-3019","article-title":"Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting","volume":"78","author":"Galmiche","year":"1997","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib62","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1099\/0022-1317-82-11-2747","article-title":"Movements of vaccinia virus intracellular enveloped virions with GFP tagged to the F13L envelope protein","volume":"82","author":"Geada","year":"2001","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib63","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1128\/JVI.74.14.6278-6286.2000","volume":"74","author":"Gherardi","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib64","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.4049\/jimmunol.162.11.6724","article-title":"IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner","volume":"162","author":"Gherardi","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib65","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1093\/jnci\/91.20.1744","article-title":"Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases","volume":"91","author":"Gnant","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2004.10.015_bib66","first-page":"3396","article-title":"Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice","volume":"59","author":"Gnant","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib67","doi-asserted-by":"crossref","unstructured":"Goebel, S.J., Johnson, G.P., Perkus, M.E., Davis, S.W., Winslow, J.P., and Paoletti, E. The complete DNA sequence of vaccinia virus. Virology 179 (1990) 247\u2013266, 517\u2013563.","DOI":"10.1016\/0042-6822(90)90294-2"},{"key":"10.1016\/j.ymthe.2004.10.015_bib68","first-page":"257","article-title":"Delivery using herpes simplex virus: an overview","volume":"246","author":"Goins","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib69","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0022-5347(05)65755-2","article-title":"Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer","volume":"166","author":"Gomella","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib70","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood-2002-05-1514","article-title":"Generating CTLs against the subdominant Epstein\u2013Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies","volume":"101","author":"Gottschalk","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2004.10.015_bib71","first-page":"6944","article-title":"Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity","volume":"62","author":"Greiner","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib72","first-page":"1093","article-title":"Evaluation of radiation effects against C6 glioma in combination with vaccinia virus\u2013p53 gene therapy","volume":"13","author":"Gridley","year":"1998","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib73","first-page":"4497","article-title":"Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects","volume":"61","author":"Grosenbach","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib74","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/pros.10130","article-title":"Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer","volume":"53","author":"Gulley","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.ymthe.2004.10.015_bib75","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1517\/14712598.4.6.901","article-title":"Vaccinia as a vector for gene delivery","volume":"4","author":"Guo","year":"2004","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib76","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1567-5769(03)00060-2","article-title":"Immunodeficiency and cancer: prospects for correction","volume":"3","author":"Hadden","year":"2003","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib77","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archinte.1978.03630320073024","article-title":"Remission of chronic lymphocytic leukemia after smallpox vaccination","volume":"138","author":"Hansen","year":"1978","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ymthe.2004.10.015_bib78","first-page":"116","article-title":"Edward Jenner's vaccine","volume":"112","author":"Henderson","year":"1997","journal-title":"Public Health Rep."},{"key":"10.1016\/j.ymthe.2004.10.015_bib79","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/sj.cgt.7700542","article-title":"Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes","volume":"9","author":"Hermiston","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib80","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1200\/JCO.2002.12.094","article-title":"Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial","volume":"20","author":"Hersey","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib81","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0042-6822(79)90533-6","article-title":"Interaction of assembled progeny pox viruses with the cellular cytoskeleton","volume":"98","author":"Hiller","year":"1979","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2004.10.015_bib82","first-page":"1837","article-title":"Vaccine therapy of established tumors in the absence of autoimmunity","volume":"9","author":"Hodge","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib83","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1016\/S0264-410X(01)00062-7","article-title":"Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules","volume":"19","author":"Hodge","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2004.10.015_bib84","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0361-090X(02)00095-8","article-title":"Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity","volume":"26","author":"Hodge","year":"2002","journal-title":"Cancer Detect. Prev."},{"key":"10.1016\/j.ymthe.2004.10.015_bib85","first-page":"7942","article-title":"Modified vaccinia virus Ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses","volume":"63","author":"Hodge","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib86","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/jnci\/92.15.1228","article-title":"Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules","volume":"92","author":"Hodge","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2004.10.015_bib87","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ijc.2910630215","article-title":"A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate","volume":"63","author":"Hodge","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2004.10.015_bib88","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1083\/jcb.200104124","article-title":"Vaccinia virus utilizes microtubules for movement to the cell surface","volume":"154","author":"Hollinshead","year":"2001","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib89","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/14712598.2.4.395","article-title":"Prostate-specific antigen vaccines for prostate cancer","volume":"2","author":"Horig","year":"2002","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib90","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s002620000146","article-title":"Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule","volume":"49","author":"Horig","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2004.10.015_bib91","first-page":"471","article-title":"Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy","volume":"1","author":"Hwang","year":"1999","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib92","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1471-4906(00)01813-5","article-title":"Viral vectors for dendritic cell-based immunotherapy","volume":"22","author":"Jenne","year":"2001","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib93","series-title":"An Inquiry into the Causes and Effects of the Variolae Vaccinae, a Disease Discovered in Some of the Western Counties of England, Particularly Near Gloucestershire, and Known by the Name of the Cow Pox","author":"Jenner","year":"1798"},{"key":"10.1016\/j.ymthe.2004.10.015_bib94","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0022-2836(64)80066-8","article-title":"The replication and coating of vaccinia DNA","volume":"10","author":"Joklik","year":"1964","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib95","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0264-410X(00)00191-2","article-title":"Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus\u2014poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans","volume":"19","author":"Kanesa-thasan","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2004.10.015_bib96","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.4049\/jimmunol.147.12.4327","article-title":"Immunobiology of infection with recombinant vaccinia virus encoding murine IL-2: mechanisms of rapid viral clearance in immunocompetent mice","volume":"147","author":"Karupiah","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib97","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1089\/104303403765255183","article-title":"Clinical protocol. Intra-lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer","volume":"14","author":"Kaufman","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib98","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1089\/104303401750298616","article-title":"A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma","volume":"12","author":"Kaufman","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib99","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1200\/JCO.2004.08.083","article-title":"Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group","volume":"22","author":"Kaufman","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib100","first-page":"3676","article-title":"Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer","volume":"8","author":"Kaufmann","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"Pt 3","key":"10.1016\/j.ymthe.2004.10.015_bib101","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1099\/0022-1317-78-3-677","article-title":"Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever","volume":"78","author":"Kettle","year":"1997","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib102","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1128\/JVI.71.3.1992-2003.1997","article-title":"Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells","volume":"71","author":"Kibler","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib103","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0960-7404(01)00020-2","article-title":"Overview analysis of adjuvant therapies for melanoma\u2014a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials","volume":"10","author":"Kim","year":"2001","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib104","first-page":"89","article-title":"Oncolytic virotherapy as a novel treatment platform for cancer","author":"Kirn","year":"2003","journal-title":"Ernst Schering Research Foundation Workshop"},{"key":"10.1016\/j.ymthe.2004.10.015_bib105","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/89901","article-title":"Replication-selective virotherapy for cancer: biological principles, risk management and future directions","volume":"7","author":"Kirn","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2004.10.015_bib106","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1126\/science.2237434","article-title":"Inhibition of the complement cascade by the major secretory protein of vaccinia virus","volume":"250","author":"Kotwal","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2004.10.015_bib107","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/335176a0","article-title":"Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins","volume":"335","author":"Kotwal","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2004.10.015_bib108","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1078-0432.CCR-03-0145","article-title":"Intratumoral vaccination and diversified subcutaneous\/intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules","volume":"10","author":"Kudo-Saito","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib109","first-page":"161","article-title":"Poxviruses as vectors for cancer immunotherapy","volume":"6","author":"Kwak","year":"2003","journal-title":"Curr. Opin. Drug Discovery Dev."},{"key":"10.1016\/j.ymthe.2004.10.015_bib110","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/viro.1994.1151","article-title":"The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis","volume":"199","author":"Lee","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2004.10.015_bib111","first-page":"3325","article-title":"Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors","volume":"54","author":"Lee","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib112","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.4049\/jimmunol.171.6.2922","article-title":"Recombinant CD63\/ME491\/neuroglandular\/NKI\/C-3 antigen inhibits growth of established tumors in transgenic mice","volume":"171","author":"Li","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib113","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1525-0016(03)00238-7","article-title":"Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles","volume":"8","author":"Lin","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib114","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.imlet.2003.11.015","article-title":"IL-15 induces IFN-beta and iNOS gene expression, and antiviral activity of murine macrophage RAW 264.7 cells","volume":"91","author":"Liu","year":"2004","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ymthe.2004.10.015_bib115","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1128\/JVI.76.10.5167-5183.2002","article-title":"Relationship between vaccinia virus intracellular cores, early mRNAs, and DNA replication sites","volume":"76","author":"Mallardo","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib116","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0093-7754(03)00233-1","article-title":"Carcinoembryonic antigen-based vaccines","volume":"30","author":"Marshall","year":"2003","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib117","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.1999.17.1.332","article-title":"Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen","volume":"17","author":"Marshall","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib118","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1200\/JCO.2000.18.23.3964","article-title":"Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses","volume":"18","author":"Marshall","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib119","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.cgt.7700538","article-title":"Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors","volume":"9","author":"Mastrangelo","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/sj.cgt.7700066","article-title":"Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma","volume":"6","author":"Mastrangelo","year":"1999","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib121","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/0-306-46817-4_34","article-title":"Intralesional vaccinia\/GM-CSF recombinant virus in the treatment of metastatic melanoma","volume":"465","author":"Mastrangelo","year":"2000","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib122","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1071059","article-title":"The danger model: a renewed sense of self","volume":"296","author":"Matzinger","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2004.10.015_bib123","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF02305769","article-title":"Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer","volume":"3","author":"McAneny","year":"1996","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib124","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.gt.3301237","article-title":"Complex interactions between the replicating oncolytic effect and the enzyme\/prodrug effect of vaccinia-mediated tumor regression","volume":"7","author":"McCart","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib125","first-page":"8751","article-title":"Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes","volume":"61","author":"McCart","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib126","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"McConkey","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2004.10.015_bib127","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.4161\/cbt.216","article-title":"Cancer-specific viruses and the development of ONYX-015","volume":"2","author":"McCormick","year":"2003","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib128","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/0042-6822(92)91246-Q","article-title":"Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: recombination-independent selectable cloning vectors","volume":"190","author":"Merchlinsky","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2004.10.015_bib129","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/sonc.2002.35243","article-title":"Melanoma vaccines","volume":"29","author":"Minev","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib130","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00262-002-0308-0","article-title":"Adjuvant immunotherapy for solid tumors: from promise to clinical application","volume":"51","author":"Mocellin","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2004.10.015_bib131","first-page":"407","article-title":"Technology evaluation: CEA-TRICOM, Therion Biologics Corp","volume":"3","author":"Morse","year":"2001","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib132","doi-asserted-by":"crossref","first-page":"11341","DOI":"10.1073\/pnas.93.21.11341","article-title":"Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety","volume":"93","author":"Moss","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2004.10.015_bib133","series-title":"Poxviridae: the Viruses and Their Replication","author":"Moss","year":"2001"},{"key":"10.1016\/j.ymthe.2004.10.015_bib134","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.4049\/jimmunol.167.3.1795","article-title":"Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells","volume":"167","author":"Motta","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib135","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.cgt.7700133","article-title":"Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation","volume":"7","author":"Mukherjee","year":"2000","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib136","first-page":"1129","article-title":"Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors","volume":"1","author":"Mulryan","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib137","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/sj.gt.3302066","article-title":"Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells","volume":"10","author":"Nagorsen","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib138","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/sj.gt.3301424","article-title":"Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity","volume":"8","author":"Nemunaitis","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib139","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/sj.cgt.7700547","article-title":"Selectively replicating viral vectors","volume":"9","author":"Nemunaitis","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib140","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2001.19.2.289","article-title":"Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer","volume":"19","author":"Nemunaitis","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib141","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.48.6.2267-2273.2004","article-title":"Efficacy of cidofovir in a murine model of disseminated progressive vaccinia","volume":"48","author":"Neyts","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ymthe.2004.10.015_bib142","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1128\/JVI.76.15.7713-7723.2002","article-title":"Immunogenicity and safety of defective vaccinia virus Lister: comparison with modified vaccinia virus Ankara","volume":"76","author":"Ober","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib143","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/10430340252809856","article-title":"Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo","volume":"13","author":"Oertli","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib144","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00002371-200405000-00009","article-title":"Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer","volume":"27","author":"Pantuck","year":"2004","journal-title":"J. Immunother."},{"key":"10.1016\/j.ymthe.2004.10.015_bib145","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1128\/JVI.23.3.608-615.1977","article-title":"Transcriptional complexity of vaccinia virus in vivo and in vitro","volume":"23","author":"Paoletti","year":"1977","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib146","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/sj.cgt.7700161","article-title":"Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody","volume":"7","author":"Paul","year":"2000","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib147","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/sj.cgt.7700461","article-title":"Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies","volume":"9","author":"Paul","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib148","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1089\/10430340050057495","article-title":"Targeted macrophage cytotoxicity using a nonreplicative live vector expressing a tumor-specific single-chain variable region fragment","volume":"11","author":"Paul","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib149","first-page":"97","article-title":"Escape mechanisms in tumor immunity: a year 2000 update","volume":"11","author":"Pawelec","year":"2000","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.ymthe.2004.10.015_bib150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1099\/0022-1317-50-1-89","article-title":"Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia","volume":"50","author":"Payne","year":"1980","journal-title":"J. Gen. Virol."},{"issue":"Pt 3","key":"10.1016\/j.ymthe.2004.10.015_bib151","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1099\/0022-1317-66-3-643","article-title":"Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo","volume":"66","author":"Payne","year":"1985","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib152","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1128\/JVI.27.1.19-27.1978","article-title":"Adsorption and penetration of enveloped and naked vaccinia virus particles","volume":"27","author":"Payne","year":"1978","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib153","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1081\/CNV-120005918","article-title":"Melanoma vaccines","volume":"20","author":"Perales","year":"2002","journal-title":"Cancer Invest."},{"key":"10.1016\/j.ymthe.2004.10.015_bib154","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1073\/pnas.081080298","article-title":"Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice","volume":"98","author":"Perera","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2004.10.015_bib155","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1093\/emboj\/19.15.3932","article-title":"Vaccinia virus infection disrupts microtubule organization and centrosome function","volume":"19","author":"Ploubidou","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2004.10.015_bib156","first-page":"411","article-title":"Mature CD83(+) dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells","volume":"9","author":"Prabakaran","year":"2002","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib157","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cgt.7700075","article-title":"Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant","volume":"7","author":"Puhlmann","year":"2000","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib158","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/10430349950018724","article-title":"Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy","volume":"10","author":"Puhlmann","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib159","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.antiviral.2004.02.003","article-title":"Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir","volume":"63","author":"Quenelle","year":"2004","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1040-8428(01)00123-8","article-title":"Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors","volume":"39","author":"Rad","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib161","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1128\/JVI.74.16.7651-7655.2000","article-title":"Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector","volume":"74","author":"Ramirez","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib162","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.4049\/jimmunol.156.9.3357","article-title":"IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression","volume":"156","author":"Rao","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib163","first-page":"6070","article-title":"Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints","volume":"62","author":"Reid","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib164","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/jgm.397","article-title":"Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer","volume":"5","author":"Rochlitz","year":"2003","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymthe.2004.10.015_bib165","first-page":"2559","article-title":"Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells","volume":"57","author":"Rodriguez","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib166","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/archderm.1974.01630050014003","article-title":"Immunotherapy of malignant melanoma with vaccinia virus","volume":"109","author":"Roenigk","year":"1974","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib167","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s002620000125","article-title":"A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity","volume":"49","author":"Rosales","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2004.10.015_bib168","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jamcollsurg.2004.01.025","article-title":"Development of effective immunotherapy for the treatment of patients with cancer","volume":"198","author":"Rosenberg","year":"2004","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.ymthe.2004.10.015_bib169","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/35077246","article-title":"Progress in human tumour immunology and immunotherapy","volume":"411","author":"Rosenberg","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2004.10.015_bib170","first-page":"2973","article-title":"Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma","volume":"9","author":"Rosenberg","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib171","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0042-6822(60)90015-5","article-title":"The rate of formation of vaccinia deoxyribonucleic acid and vaccinia virus","volume":"10","author":"Salzman","year":"1960","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2004.10.015_bib172","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1073\/pnas.88.9.4025","article-title":"Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo","volume":"88","author":"Sambhi","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2004.10.015_bib173","first-page":"57","article-title":"Structural studies on adenoviruses","volume":"272","author":"San Martin","year":"2003","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib174","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0090-4295(98)00539-1","article-title":"Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer","volume":"53","author":"Sanda","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.ymthe.2004.10.015_bib175","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1099\/0022-1317-81-1-47","article-title":"The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles","volume":"81","author":"Sanderson","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib176","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1358\/dnp.2000.13.2.858467","article-title":"Melanoma vaccines","volume":"13","author":"Schadendorf","year":"2000","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.ymthe.2004.10.015_bib177","first-page":"5058","article-title":"Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice","volume":"62","author":"Schmitz","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib178","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1155\/S111072430320704X","article-title":"Metastatic breast tumour regression following treatment by a gene-modified vaccinia virus expressing MUC1 and IL-2","volume":"2003","author":"Scholl","year":"2003","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib179","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00002371-200009000-00007","article-title":"Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer","volume":"23","author":"Scholl","year":"2000","journal-title":"J. Immunother."},{"key":"10.1016\/j.ymthe.2004.10.015_bib180","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/sj.cgt.7700351","article-title":"Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1\/melan-A antigen","volume":"8","author":"Schutz","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib181","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0264-410X(03)00535-8","article-title":"Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu\/Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes","volume":"22","author":"Shalaby","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2004.10.015_bib182","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1128\/JVI.70.10.7103-7107.1996","article-title":"Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo","volume":"70","author":"Sharma","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib183","series-title":"Adenoviridae: the Viruses and Their Replication","author":"Shenk","year":"2001"},{"key":"10.1016\/j.ymthe.2004.10.015_bib184","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.ju.0000070925.10039.23","article-title":"Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model","volume":"170","author":"Siemens","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib185","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10096-003-1075-3","article-title":"Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1","volume":"23","author":"Slobod","year":"2004","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ymthe.2004.10.015_bib186","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ijantimicag.2003.10.010","article-title":"Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice","volume":"23","author":"Smee","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"Pt 6","key":"10.1016\/j.ymthe.2004.10.015_bib187","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1099\/0022-1317-72-6-1349","article-title":"Nucleotide sequence of 42 kbp of vaccinia virus strain WR from near the right inverted terminal repeat","volume":"72","author":"Smith","year":"1991","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib188","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0378-1119(83)90163-4","article-title":"Infectious poxvirus vectors have capacity for at least 25000 base pairs of foreign DNA","volume":"25","author":"Smith","year":"1983","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2004.10.015_bib189","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-065X.1997.tb01012.x","article-title":"Vaccinia virus immune evasion","volume":"159","author":"Smith","year":"1997","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2004.10.015_bib190","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus","volume":"83","author":"Smith","year":"2002","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib191","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1099\/0022-1317-81-5-1223","article-title":"Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins","volume":"81","author":"Smith","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib192","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0966-842X(01)02256-9","article-title":"Assembly of vaccinia virus revisited: de novo membrane synthesis or acquisition from the host?","volume":"10","author":"Sodeik","year":"2002","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib193","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-3-642-59410-6_23","article-title":"Cytotoxic T-cell induction in metastatic melanoma patients undergoing recombinant vaccinia virus-based immuno-gene therapy","volume":"160","author":"Spagnoli","year":"2002","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib194","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0092-8674(92)90273-F","article-title":"Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein","volume":"71","author":"Spriggs","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2004.10.015_bib195","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1034\/j.1600-0463.2003.11107813.x","article-title":"Clinical application of dendritic cells in cancer vaccination therapy","volume":"111","author":"Svane","year":"2003","journal-title":"APMIS"},{"key":"10.1016\/j.ymthe.2004.10.015_bib196","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0092-8674(95)90076-4","article-title":"Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity","volume":"81","author":"Symons","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2004.10.015_bib197","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1128\/JVI.78.2.768-778.2004","article-title":"Dual stimulation of Epstein\u2013Barr virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma","volume":"78","author":"Taylor","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib198","first-page":"41","article-title":"Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen","volume":"8","author":"Terasawa","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib199","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/jgm.205","article-title":"Replication-deficient vaccinia virus gene therapy vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells","volume":"3","author":"Timiryasova","year":"2001","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymthe.2004.10.015_bib200","first-page":"845","article-title":"Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis","volume":"14","author":"Timiryasova","year":"1999","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib201","first-page":"133","article-title":"Antitumor effect of vaccinia virus in glioma model","volume":"11","author":"Timiryasova","year":"1999","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib202","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s002620100214","article-title":"Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2","volume":"50","author":"Trevor","year":"2001","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2004.10.015_bib203","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jnci\/87.13.982","article-title":"Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia\u2013CEA vaccine","volume":"87","author":"Tsang","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2004.10.015_bib204","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/(SICI)1097-0142(20000401)88:7<1650::AID-CNCR20>3.0.CO;2-L","article-title":"Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus","volume":"88","author":"Valdez Graham","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2004.10.015_bib205","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4049\/jimmunol.164.1.371","article-title":"IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-gamma and nitric oxide synthetase 2","volume":"164","author":"van Den Broek","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib206","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/S0264-410X(01)00086-X","article-title":"Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime\u2013boost regimens","volume":"19","author":"van der Burg","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2004.10.015_bib207","first-page":"1019","article-title":"Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine","volume":"8","author":"van der Burg","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"Pt 4","key":"10.1016\/j.ymthe.2004.10.015_bib208","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1099\/0022-1317-79-4-877","article-title":"Intracellular and extracellular vaccinia virions enter cells by different mechanisms","volume":"79","author":"Vanderplasschen","year":"1998","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib209","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1073\/pnas.95.13.7544","article-title":"Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope","volume":"95","author":"Vanderplasschen","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2004.10.015_bib210","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1128\/JVI.71.5.4032-4041.1997","article-title":"A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors","volume":"71","author":"Vanderplasschen","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib211","first-page":"23","article-title":"Immunotherapy in colorectal cancer","volume":"78","author":"Wallack","year":"1981","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymthe.2004.10.015_bib212","first-page":"160","article-title":"A new approach in immunotherapy with vaccinia oncolysates","volume":"28","author":"Wallack","year":"1977","journal-title":"Surg. Forum"},{"key":"10.1016\/j.ymthe.2004.10.015_bib213","doi-asserted-by":"crossref","unstructured":"Wallack, M.K., et al. (1998). Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J. Am. Coll. Surg. 187: 69\u201377; discussion 77\u201379.","DOI":"10.1016\/S1072-7515(98)00097-0"},{"key":"10.1016\/j.ymthe.2004.10.015_bib214","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1128\/JVI.75.23.11651-11663.2001","article-title":"Vaccinia virus intracellular movement is associated with microtubules and independent of actin tails","volume":"75","author":"Ward","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib215","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1128\/JVI.75.10.4802-4813.2001","article-title":"Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein\u2013B5R membrane protein chimera","volume":"75","author":"Ward","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib216","doi-asserted-by":"crossref","first-page":"11437","DOI":"10.1128\/JVI.75.23.11437-11448.2001","article-title":"Vaccinia virus infection disarms the mitochondrion-mediated pathway of the apoptotic cascade by modulating the permeability transition pore","volume":"75","author":"Wasilenko","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib217","doi-asserted-by":"crossref","first-page":"14345","DOI":"10.1073\/pnas.2235583100","article-title":"Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis","volume":"100","author":"Wasilenko","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2004.10.015_bib218","first-page":"183","article-title":"In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy","volume":"116","author":"Whitman","year":"1994","journal-title":"Surgery"},{"key":"10.1016\/j.ymthe.2004.10.015_bib219","first-page":"6956","article-title":"Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen","volume":"63","author":"Yang","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib220","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.4049\/jimmunol.164.8.4204","article-title":"Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3","volume":"164","author":"Yang","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2004.10.015_bib221","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1089\/104303403322495016","article-title":"Phase I\/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients","volume":"14","author":"Zajac","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib222","first-page":"4567","article-title":"Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules","volume":"58","author":"Zajac","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib223","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/sj.cgt.7700452","article-title":"Inhibition of tumor growth by recombinant vaccinia virus expressing GA733\/CO17-1A\/EpCAM\/KSA\/KS1-4 antigen in mice","volume":"9","author":"Zaloudik","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib224","first-page":"4570","article-title":"Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen","volume":"57","author":"Zaremba","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2004.10.015_bib225","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.cgt.7700549","article-title":"Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers","volume":"9","author":"Zeh","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2004.10.015_bib226","first-page":"24","article-title":"Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox\u2013CEA vaccine","volume":"6","author":"Zhu","year":"2000","journal-title":"Clin. Cancer Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001604015072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001604015072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T23:00:32Z","timestamp":1682895632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001604015072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":226,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S1525001604015072"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2004.10.015","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}